top of page
  • Writer's pictureFutureMeds

FutureMeds Provides World-leading Expertise in Osteoporosis Research

Updated: Jan 24, 2023

Almost all FDA-approved osteoporosis medications have been investigated by FutureMeds’ Senior Medical Director, Professor Edward Czerwinski MD PhD.

Following the April 2020 acquisition of Krakow Medical Centre (KCM), KCM founder and world-renowned specialist and leader in the field of osteoporosis, prof. Edward Czerwinski MD PhD, was appointed Senior Medical Director. FutureMeds now stand as world leaders in osteoporosis clinical trials.

Edward is a Professor of the Jagiellonian University with 50 years of experience as a practising orthopaedic surgeon in addition to being an active university lecturer and scientist. As a former KCM director he and his team led 200 trials across a wide range of therapy areas such as phase II-IV cardiology, dermatology, rheumatology, neurology, nephrology and gastroenterology. He has been PI in 58 trials, in which 2,700 patients were enrolled.

In 46 osteoporosis trials in which over 1,650 patients have been participating, 12 osteoporosis drugs & compounds were investigated, including Alendronate, Ibandronate, Risedronate, Zoledronate, Strontium ranelate, Cathepsin, Lasofoxifene, Arzoxifene, Tibolone, Denosumab, Romosozumab and Abaloparatide. As a result of the team’s extensive work, almost all osteoporosis medications that have received FDA approval have been tested by Professor Edward Czerwinski’s clinical trial team.

24 conferences were organized by Professor Czerwinski in Poland, including the World Congress on Osteoporosis in 2018 and 8 Central European Congress on Osteoporosis. His current international memberships include scientific committees of IOF, EULAR, EFFORT and the boards of 10 scientific international magazines. Additionally, he is the founder and manager of Polish Portal on Osteoporosis and the author of over 530 publications.

Under his medical direction, FutureMeds’ Dedicated Site Network drives 3 times more patients per site than traditional sites. The high-performing trial centres of FutureMeds’ Dedicated Site Network enhance patient experience and enable clients to access a wider and more diverse patient community.

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.

bottom of page